Strategies to Improve the Clinical Performance of Chimeric Antigen Receptor-Modified T Cells for Cancer

Title:Strategies to Improve the Clinical Performance of Chimeric Antigen Receptor-Modified T Cells for Cancer

Volume: 13 Issue: 1

Author(s): Qing Zhang, Huizhong Li, Jie Yang, Liantao Li, Baofu Zhang, Jia Li and Junnian Zheng

Affiliation:

Keywords: Adoptive cell therapy, chimeric antigen receptor, T cell, cancer immunotherapy, cancer gene therapy, clinical trial, T cell receptor, single chain fragment variable

Abstract: Clinical trials of chimeric antigen receptor (CAR)-modified T cells have shown promise in hematologic malignancies. However, in solid tumors, the clinical responses have been less impressive. It is important to determine how to further improve the clinical effects of CAR-modified T cells. In this review, we focus on recent clinical trials and analyze the factors that determine clinical responses, including the following: 1) the composition of the CAR; 2) the preparation of CAR-modified T Cells; 3) the clinical treatment schedule; 4) the patient characteristics. We also propose future Strategies that must be investigated before the technology can be used in a wider range of clinical applications.

Cite this article as:

Zhang Qing, Li Huizhong, Yang Jie, Li Liantao, Zhang Baofu, Li Jia and Zheng Junnian, Strategies to Improve the Clinical Performance of Chimeric Antigen Receptor-Modified T Cells for Cancer, Current Gene Therapy 2013; 13 (1) . https://dx.doi.org/10.2174/1566523211313010007